Regulatory News:
Eurofins Lancaster Laboratories, part of Eurofins Scientific
(Paris:ERF) (EUFI.PA), the world leader in bioanalytical testing,
announces strategic plans for the expansion of its Dungarvan,
Ireland campus, including development of a new building as well as
expansion of its current facility. Further, as a major employer in
the South East of Ireland, Eurofins Lancaster Laboratories is set
to increase its workforce to over 500 staff by 2021 with this
investment by its parent company, Eurofins Scientific. Over 175 new
jobs have been created in the past 24 months.
The launch of this major building expansion programme combines
the expansion of the existing 2,700m2 laboratory with an additional
4,400m2 extension, as well as the development of a 1,800m2 second
site on the campus located in the IDA Business Park, Dungarvan.
This means that the project will bring the Group’s capacity to
almost 9,000m2 of state-of–the-art laboratory surface to serve the
biopharmaceutical industry in Ireland and the UK. The project is in
the planning submission phase and building works are planned to
commence in Q4 2016. The project is another example of the
commitment of Eurofins Scientific to continued growth and
investment in its laboratory operations in the region.
“This expansion is the result of successfully growing strategic
partnerships with our clients and the value we bring to them and
their target markets. And it reinforces Eurofins’ absolute
commitment to aggressively funding growth to enhance the way we
serve our customers as well as build the best and widest-reaching
testing network in the biopharmaceutical market,” said Timothy S.
Oostdyk, Ph.D., Chairman, Eurofins Lancaster Laboratories, and
Group Senior Vice President, Eurofins BioPharma Product
Testing.
Carmel Fitzpatrick, Managing Director, Eurofins Lancaster
Laboratories in Ireland, said, “We currently serve 18 of the top 20
global pharmaceutical companies and our success is attributable
mostly to the excellent commitment and technical capability of our
people. Our broad base of clients means we work on a diverse range
of products and development projects which offers an excellent
scope for continuous learning and development of technical depth
that is unparalleled. We invest heavily in our internal training
programmes, and we are grateful to be supported by the IDA and the
Skillnets to deliver technical competency in our team that is world
class. We also pride ourselves on a service offering that meets the
complex and varying needs of our clients, many of whom avail of all
our service tiers, whether in-house or at the client facility. Our
in-house testing services are complemented by our innovative and
award-winning Professional Scientific Services (PSS) programme that
places full-time analysts, technicians, scientists and technical
support personnel managed by us directly at the client facility to
provide long term staffing needs while maintaining the same
services, expertise and cGMP compliance available at our facility
in Dungarvan. We have PSS teams based at a variety of client
locations in Ireland and UK.”
Welcoming the announcement Minister for Jobs, Enterprise and
Innovation, Mary Mitchell O'Connor said: "It’s great to see an
established successful company like Eurofins expanding its
operations further in Waterford with the addition of over 160 staff
over the next five years. That’s on top of the 175 jobs created in
the past two years. A key priority for me as Minister is
encouraging more companies to set up in our regions. Companies
setting up and creating jobs in our regions ensures that there are
opportunities for positive knock-on effects in the surrounding
areas. Only a strong economy supporting people at work can pay for
the services needed to create a fair society. Already a major
employer in this key regional location, this further expansion and
substantial number of new jobs will benefit the entire South
East Region. It demonstrates great commitment by Eurofins’ parent
company, Eurofins Scientific. I congratulate the company and
their workforce and wish them continued success.”
CEO of IDA Ireland, Martin Shanahan said “This investment
demonstrates Eurofins Lancaster Laboratories’ commitment to
Dungarvan, and the large cluster of biopharma companies based in
Ireland. Achieving increased levels of investment in regional
locations is an important focus of IDA’s strategy ‘Winning – FDI
2015-2019’ and today’s announcement is an important step in that
direction. I wish Eurofins every success as they continue to grow
their operations in the South East Region.”
For more information about Eurofins, please visit
www.eurofins.com.
Notes for the editor:About Eurofins Lancaster
Laboratories, Inc.Founded in 1961, global leader Eurofins
Lancaster Laboratories provides comprehensive bio/pharmaceutical
laboratory services for all stages of the drug development process
and supports all functional areas of bio/pharmaceutical
manufacturing, including method development, microbiology, process
validation and quality control.
As a member of Eurofins Scientific’s BioPharma Product Testing
Group—the largest network of harmonized bio/pharmaceutical GMP
product testing laboratories worldwide—Eurofins Lancaster
Laboratories partners with world’s largest pharmaceutical and
biopharmaceutical companies to transform their science into
outstanding solutions. With a global capacity of more than 625,000
square feet, its network of GMP laboratories operates under the
same strict quality procedures, LIMS, centralized billing system
and online data access portal, LabAccess.comSM, across 22 locations
worldwide.
In addition to these laboratory locations, Eurofins Lancaster
Laboratories has teams of scientists placed at more than 60 client
facilities worldwide through its Professional Scientific Services
insourcing program. www.EurofinsLancasterLabs.com
Eurofins – a global leader in bio-analysisEurofins
Scientific believes it is the world leader in food, environment and
pharmaceutical products testing, as well as one of the global
market leaders in agroscience, genomics, discovery pharmacology and
central laboratory services. In addition, Eurofins is one of the
key emerging players in specialty clinical diagnostic testing in
Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients' increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160613005431/en/
Investor RelationsEurofins Scientific GroupPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024